Evidence map›Paper›PMID 41419168›Full record

ArticleJournal of molecular biology2026

Sequence Engineering at Non-motif Modulator Residues Yields a Peptide That Effectively Targets a Single PDZ Protein in a Disease-relevant Cellular Context.

Jeanine F Amacher, Patrick R Cushing, Lars Vouilleme, Sierra N Cullati, Bin Deng, Scott A Gerber, Prisca Boisguerin, Dean R Madden

Abstract read
In one paragraph

Article in Journal of molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jeanine F AmacherDept. of Biochemistry & Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Patrick R CushingDept. of Biochemistry & Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Lars VouillemeInstitute of Medical Immunology, Charité - Universitätsmedizin, 10115 Berlin, Germany.
Sierra N CullatiDept. of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Bin DengDept. of Biology, VBRN Proteomics Facility, University of Vermont, Burlington, VT 05405, USA.
Scott A GerberDept. of Biochemistry & Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA; Dept. of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA.
Prisca BoisguerinInstitute of Medical Immunology, Charité - Universitätsmedizin, 10115 Berlin, Germany.
Dean R MaddenDept. of Biochemistry & Cell Biology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA. Electronic address: dean.madden@dartmouth.edu.

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Julie Dragon · 2012 to 2026
$58.4M
Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MIERKE, DALE F · 2016 to 2025
$25.9M
Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 2018 to 2026
$13.9M
Molecular and Cellular Biology at DartmouthT32GM008704 · NIGMS · DARTMOUTH COLLEGE · PI COMPTON, DUANE A. · 1998 to 2018
$6.8M
TRANSLATIONAL RESEARCH COREP30GM106394 · NIGMS · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 2013 to 2017
$6.1M
Preclinical development of CFTR stabilizers targeting the CAL PDZ domainR01DK101541 · NIDDK · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2014 to 2017
$1.9M
NIDDK NIH HHS P30 DK117469NIDDK NIH HHS R01 DK101541NIGMS NIH HHS P20 GM103449NIGMS NIH HHS P20 GM113132NIGMS NIH HHS P30 GM106394NIGMS NIH HHS T32 GM008704
6 · The paper itself

Abstract

PDZ interaction networks are finely-tuned products of evolution. These widespread binding domains recognize short linear motifs (SLiMs), usually at the C-terminus of their interacting partners, and are involved in trafficking and signaling pathways, the formation of tight junctions, and scaffolding of the post-synaptic density of neurons, amongst other roles. Typically, a single PDZ domain binds multiple targets; conversely, each PDZ-binding protein engages several PDZ domains, dependent on cellular conditions. Historical PDZ binding motifs rely on two key positions for binding. However, previous insights on modulator, or non-motif, selectivity preferences reveal that these limited motifs are insufficient to describe PDZ-mediated interactomes, consistent with the observation that the degree of promiscuity is much more limited than predicted by defined binding classes. Here, we use these principles to engineer and test a peptide-based inhibitor capable of interacting with a single PDZ domain-containing protein in a disease-relevant cellular system. We first interrogate a previously developed sequence selective for cystic fibrosis transmembrane conductance regulator (CFTR)-Associated Ligand (CAL), one of five PDZ domains known to bind the CFTR C-terminus, probing for off-target PDZ partners. Once identified, we use parallel biochemical and structural refinement to eliminate these interactions and introduce a CAL PDZ inhibitor with unprecedented PDZ domain selectivity. We test and verify specificity using relevant cellular PDZ target networks in a mass spectrometry-based approach. Our resultant selective inhibitor enhances chloride efflux when applied to polarized patient bronchial epithelial cells, as well as confirms that engineering an effectively single-PDZ peptide is possible when modulator preferences are applied.

Indexed as

PDZ DomainsPeptidesProtein EngineeringAmino Acid MotifsAmino Acid SequenceBinding SitesCystic Fibrosis Transmembrane Conductance RegulatorHumansMembrane ProteinsProtein BindingCystic Fibrosis Transmembrane Conductance RegulatorMembrane ProteinsPeptidesCALCFTRPDZpeptide selectivityTIP-1

Identifiers

PMID41419168
PMCPMC13170487

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.